

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 July 2022 (14.07.2022)



(10) International Publication Number
WO 2022/150521 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2022/011504

(22) International Filing Date:

06 January 2022 (06.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/134,412 06 January 2021 (06.01.2021) US

(71) Applicant: **PALLEON PHARMACEUTICALS INC.**

[US/US]; 266 Second Avenue, 2nd Floor, Waltham, Massachusetts 02451 (US).

(72) Inventors: **PENG, Li**; 6 Bicentennial Drive, Lexington, Massachusetts 02421 (US). **CHE, Jenny**; 7 Hickory Road, Ashland, Massachusetts 01721 (US). **XU, Lihui**; 58 Wolcott Road, Chestnut Hill, Massachusetts 02467 (US).

(74) Agent: **DAVENPORT, Andrew M.**; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-PD-L1 ANTIBODIES AND FUSION PROTEINS THEREOF

(57) Abstract: The invention relates generally to anti-PD-L1 antibodies, and recombinant sialidase and anti-PD-L1 immunoglobulin antigen-binding domain fusion proteins. The invention also provides antibody conjugates including a sialidase and an anti-PD-L1 antibody or a portion thereof. The invention further relates to methods of using the antibodies, sialidase fusion proteins, or antibody conjugates for treating cancer.



WO 2022/150521 A1